Background
Background Hyperprolactinaemia Hyperprolactinaemia has for decades been an inevitable and has for decades been an inevitable and neglected side-effect of antipsychotic neglected side-effect of antipsychotic medication.The recent introduction of medication.The recent introduction of prolactin-sparing antipsychotic agents prolactin-sparing antipsychotic agents makes a re-examination of this problem makes a re-examination of this problem timely. timely.
Aims Aims To review the literature on
To review the literature on antipsychotic-induced hyperprolactinaeantipsychotic-induced hyperprolactinaemia and its consequences. mia and its consequences.
Method
Method A search was made of the A search was made of the Medline database (1966^2002) for key Medline database (1966^2002) for key articles, supplemented by crossarticles, supplemented by crossreferencing. referencing.
Results

Results During antipsychotic
During antipsychotic treatment prolactin concentrations can treatment prolactin concentrations can rise to ten times normallevels or above, rise to ten times normallevels or above, and existing data indicate that17^78% of and existing data indicate that17^78% of female patients have amenorrhoea with or female patients have amenorrhoea with or without galactorrhoea. Survey data, without galactorrhoea. Survey data, however, suggestthat clinicians however, suggestthat clinicians underestimate the prevalence of these underestimate the prevalence of these conditions.Long-term consequences of conditions.Long-term consequences of antipsychotic-related hypo-oestrogenism antipsychotic-related hypo-oestrogenism require further research but are likely to require further research but are likely to include premature bone loss. include premature bone loss.
Conclusions Conclusions Antipsychotic-induced
Antipsychotic-induced hyperprolactinaemia should become a hyperprolactinaemia should become a focus of interest in the drug treatment of focus of interest in the drug treatment of psychiatric patients. psychiatric patients.
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It is thought that the mesolimbic dopamiIt is thought that the mesolimbic dopaminergic system is pivotal in the control of nergic system is pivotal in the control of psychotic symptoms, and in recent years psychotic symptoms, and in recent years drug development has focused on optimisdrug development has focused on optimising the effect of antipsychotic agents in this ing the effect of antipsychotic agents in this system. The aim was to reduce side-effects system. The aim was to reduce side-effects caused by antidopaminergic action in noncaused by antidopaminergic action in nonmesolimbic regions. Most attention has mesolimbic regions. Most attention has been given to the various movement disbeen given to the various movement disorders caused by dopaminergic blockade orders caused by dopaminergic blockade in the striatum. However, the antidopamiin the striatum. However, the antidopaminergic effect at the pituitary gland and the nergic effect at the pituitary gland and the resulting increase in prolactin production resulting increase in prolactin production have been relatively neglected, and have been relatively neglected, and clinicians underestimate their prevalence clinicians underestimate their prevalence (Hellewell, 1998) . (Hellewell, 1998) .
In this article we discuss the physiology In this article we discuss the physiology of prolactin secretion, the effect of conof prolactin secretion, the effect of conventional and atypical antipsychotic drugs ventional and atypical antipsychotic drugs on circulating prolactin levels, and the on circulating prolactin levels, and the consequences of hyperprolactinaemia on consequences of hyperprolactinaemia on endocrine function in women. Since antiendocrine function in women. Since antipsychotic treatment is often initiated when psychotic treatment is often initiated when patients are in their late teens or twenties patients are in their late teens or twenties and continued for years or decades, we also and continued for years or decades, we also consider the possible consequences of consider the possible consequences of prolonged endocrine dysfunction. prolonged endocrine dysfunction.
PROLACTIN PHYSIOLOGY PROLACTIN PHYSIOLOGY
Prolactin is secreted in a pulsatile manner Prolactin is secreted in a pulsatile manner by the anterior pituitary gland. There are by the anterior pituitary gland. There are 13 or 14 peaks per day, with an interpulse 13 or 14 peaks per day, with an interpulse interval of about 95 min. The mean pulse interval of about 95 min. The mean pulse amplitude above the preceding nadir is on amplitude above the preceding nadir is on average about 20-30% of the upper normal average about 20-30% of the upper normal value (Veldhuis & Johnson, 1988) . Dayvalue (Veldhuis & Johnson, 1988) . Daytime levels and peak amplitudes vary time levels and peak amplitudes vary considerably between individuals, and in considerably between individuals, and in women levels are higher at the middle and women levels are higher at the middle and during the second half of the menstrual during the second half of the menstrual cycle. Transient and mild increases of procycle. Transient and mild increases of prolactin secretion occur in response to meals, lactin secretion occur in response to meals, stress and sexual activity. The upper limit stress and sexual activity. The upper limit of unstimulated prolactin levels in men of unstimulated prolactin levels in men and women varies between laboratories, and women varies between laboratories, ranging between 350 mU/l and 550 mU/l. ranging between 350 mU/l and 550 mU/l.
(Serum prolactin concentrations are (Serum prolactin concentrations are expressed in mU/l or ng/ml. Because expressed in mU/l or ng/ml. Because laboratories use different standards the laboratories use different standards the conversion factor varies between these conversion factor varies between these units. In this article we use mU/l because units. In this article we use mU/l because this is more commonly employed in Europe. this is more commonly employed in Europe. Other reported values are described in Other reported values are described in terms of magnitude of change compared terms of magnitude of change compared with baselines or upper limits of the normal with baselines or upper limits of the normal range.) range.)
The main physiological function of The main physiological function of prolactin is to cause breast enlargement prolactin is to cause breast enlargement during pregnancy and milk production during pregnancy and milk production during lactation. The reductions in libido during lactation. The reductions in libido and fertility that are associated with and fertility that are associated with nursing may have evolutionary advantages. nursing may have evolutionary advantages. Prolactin is also involved in promoting Prolactin is also involved in promoting maternal behaviour in animals, but whether maternal behaviour in animals, but whether it is involved in the regulation of this it is involved in the regulation of this behaviour in humans is not known. behaviour in humans is not known.
Regulation of prolactin secretion Regulation of prolactin secretion
Hypothalamic dopamine is the predomiHypothalamic dopamine is the predominant prolactin-inhibiting factor. Released nant prolactin-inhibiting factor. Released into the portal hypophysial circulation it into the portal hypophysial circulation it binds to D binds to D 2 2 receptors on the membrane of receptors on the membrane of pituitary lactotroph cells. Stimulation of pituitary lactotroph cells. Stimulation of D D 2 2 receptors has inhibitory effects on receptors has inhibitory effects on prolactin gene transcription, synthesis and prolactin gene transcription, synthesis and release and these effects are mediated in a release and these effects are mediated in a complex fashion, involving several signal complex fashion, involving several signal transduction systems. Other substances transduction systems. Other substances identified as prolactin-inhibiting factors, identified as prolactin-inhibiting factors, for example gonadotrophin-associated for example gonadotrophin-associated protein, gamma-aminobutyric acid (GABA) protein, gamma-aminobutyric acid (GABA) and acetylcholine, are of uncertain and acetylcholine, are of uncertain physiological significance in humans. physiological significance in humans.
Serotonin (5-HT) has a stimulatory role Serotonin (5-HT) has a stimulatory role in prolactin regulation by mediating nocin prolactin regulation by mediating nocturnal surges and suckling-induced rises turnal surges and suckling-induced rises (Tuomisto & Mannisto, 1985) . The seroto- (Tuomisto & Mannisto, 1985) . The serotonergic neurons involved project from the nergic neurons involved project from the dorsal raphe nucleus to the medial basal dorsal raphe nucleus to the medial basal hypothalamus and exert their effects via hypothalamus and exert their effects via 5-HT 5-HT 1A 1A and 5-HT and 5-HT 2 2 receptor mechanisms. receptor mechanisms. Oestrogens can modulate prolactin secreOestrogens can modulate prolactin secretion in response to reproductive events tion in response to reproductive events using various mechanisms. They can inhibit using various mechanisms. They can inhibit hypothalamic dopamine synthesis, reduce hypothalamic dopamine synthesis, reduce the number of pituitary D the number of pituitary D 2 2 receptors, receptors, enhance prolactin gene transcription and enhance prolactin gene transcription and synthesis and are involved in mitotic synthesis and are involved in mitotic activity of lactotrophs (Molitch, 1995) . A activity of lactotrophs (Molitch, 1995) . A number of peptide neurotransmitters have number of peptide neurotransmitters have prolactin-releasing properties in animals prolactin-releasing properties in animals but their physiological role in humans is but their physiological role in humans is uncertain. uncertain.
EFFECTS OF PSYCHOTROPIC EFFECTS OF PSYCHOTROPIC DRUGS ON PROLACTIN DRUGS ON PROLACTIN SECRETION SECRETION
In drug-free patients with acute or chronic In drug-free patients with acute or chronic major psychiatric disorders prolactin secremajor psychiatric disorders prolactin secretory patterns measured throughout the day tory patterns measured throughout the day are no different from those in normal conare no different from those in normal controls (Linkowski trols (Linkowski et al et al, 1989; Rao , 1989; Rao et al et al, , 1994 ). An elevation of baseline prolactin 1994). An elevation of baseline prolactin levels in medicated psychiatric patients levels in medicated psychiatric patients seems therefore to be related to drug effects seems therefore to be related to drug effects rather than to the illness itself. rather than to the illness itself.
Conventional antipsychotic drugs Conventional antipsychotic drugs
All conventional antipsychotic drugs block All conventional antipsychotic drugs block D D 2 2 receptors on lactotroph cells and thus receptors on lactotroph cells and thus remove the main inhibitory influence on remove the main inhibitory influence on prolactin secretion. Elevation of prolactin prolactin secretion. Elevation of prolactin levels occurs within a few hours of treatlevels occurs within a few hours of treatment initiation (Meltzer & Fang, 1976) . ment initiation (Meltzer & Fang, 1976) . Prospective studies with an open or Prospective studies with an open or double-blind design have shown that double-blind design have shown that medium-term treatment (3-9 weeks) with medium-term treatment (3-9 weeks) with therapeutic dosages increases mean baseline therapeutic dosages increases mean baseline prolactin levels up to ten-fold (Meltzer & prolactin levels up to ten-fold (Meltzer & Fang, 1976; Gruen Fang, 1976; Gruen et al et al, 1978; Oseko , 1978; Oseko et et al al, 1988; Kuruvilla , 1988; Kuruvilla et al et al, 1992; Arvanitis , 1992; Arvanitis et al et al, 1997; Crawford , 1997; Crawford et al et al, 1997) . Low , 1997). Low daily dosing regimens (e.g. 200 mg chlordaily dosing regimens (e.g. 200 mg chlorpromazine) can cause significant prolactin promazine) can cause significant prolactin elevations (Meltzer & Fang, 1976) , and elevations (Meltzer & Fang, 1976) , and levels have been reported to increase in a levels have been reported to increase in a dose-dependent manner up to about 600 mg dose-dependent manner up to about 600 mg chlorpromazine equivalents (Meltzer chlorpromazine equivalents (Meltzer et al et al, , 1983; Green & Brown, 1988) . A partial 1983; Green & Brown, 1988) . A partial tolerance may occur during chronic treattolerance may occur during chronic treatment (Brown & Laughren, 1981) although ment (Brown & Laughren, 1981) although patients treated for several years still have patients treated for several years still have significantly higher baseline prolactin levels significantly higher baseline prolactin levels than untreated healthy controls (Rivera than untreated healthy controls (Rivera et al et al, , 1976; Zelaschi 1976; Zelaschi et al et al, 1996 Zelaschi et al et al, ). , 1996 . Women have significantly greater proWomen have significantly greater prolactin elevations than men during chronic lactin elevations than men during chronic antipsychotic treatment with equivalent antipsychotic treatment with equivalent doses (Wode-Helgodt doses (Wode-Helgodt et al et al, 1977; Kuruvilla , 1977; Kuruvilla et al et al, 1992; Smith , 1992; Smith et al et al, 2002) . In a cross-, 2002). In a crosssectional study of 402 patients (Kinon & sectional study of 402 patients (Kinon & Gilmore, 2001) in whom prolactin levels Gilmore, 2001) in whom prolactin levels were measured after a minimum of 3 were measured after a minimum of 3 months' treatment with conventional antimonths' treatment with conventional antipsychotics or risperidone, 59% of women psychotics or risperidone, 59% of women and 42% of men had a prolactin level and 42% of men had a prolactin level above the upper limit of normal. above the upper limit of normal.
When oral antipsychotic therapy is When oral antipsychotic therapy is discontinued, baseline prolactin levels may discontinued, baseline prolactin levels may take up to 3 weeks to return to the normal take up to 3 weeks to return to the normal range (Turkington, 1972) , depending on range (Turkington, 1972) , depending on the half-life of the drug and its metabolites the half-life of the drug and its metabolites as well as storage in fatty tissues. In the case as well as storage in fatty tissues. In the case of depot medication normalisation may of depot medication normalisation may take as long as 6 months (Wistedt take as long as 6 months (Wistedt et al et al, , 1981 Clozapine, quetiapine and olanzapine are Clozapine, quetiapine and olanzapine are reported either to cause no increase in proreported either to cause no increase in prolactin secretion at all or to increase it only lactin secretion at all or to increase it only transiently and mildly (Meltzer transiently and mildly (Meltzer et al et al, , 1979; Small 1979; Small et al et al, 1997; Tollefson & , 1997; Tollefson & Kuntz, 1999) . In contrast, risperidone and Kuntz, 1999). In contrast, risperidone and amisulpride cause a marked and sustained amisulpride cause a marked and sustained increase in serum prolactin levels. increase in serum prolactin levels.
In a randomised, double-blind, parallelIn a randomised, double-blind, parallelgroup study Gruender group study Gruender et al et al (1999) (1999) compared treatment with amisulpride compared treatment with amisulpride (1000 mg daily) and oral flupentixol (1000 mg daily) and oral flupentixol (25 mg daily) in 32 men and women with (25 mg daily) in 32 men and women with schizophrenia who were free of oral antischizophrenia who were free of oral antipsychotic medication for at least 4 weeks psychotic medication for at least 4 weeks and depot neuroleptics for at least 3 and depot neuroleptics for at least 3 months. After 4 weeks of treatment mean months. After 4 weeks of treatment mean baseline prolactin levels were significantly baseline prolactin levels were significantly elevated in both groups, in the amisulpride elevated in both groups, in the amisulpride group by a factor of 10 and in the flupengroup by a factor of 10 and in the flupentixol group by a factor of 5. The difference tixol group by a factor of 5. The difference between amisulpride and flupentixol between amisulpride and flupentixol treatment was significant in the women treatment was significant in the women patients. patients.
Kleinberg Kleinberg et al et al (1999) pooled the data (1999) pooled the data from two large, randomised, double-blind, from two large, randomised, double-blind, controlled clinical trials comparing 8 weeks controlled clinical trials comparing 8 weeks of treatment with fixed daily doses of of treatment with fixed daily doses of risperidone (1 mg, 2 mg, 4 mg, 6 mg, 8 mg, risperidone (1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg and 16 mg), haloperidol 10 mg, 12 mg and 16 mg), haloperidol (10 mg and 20 mg) and placebo. Prolactin (10 mg and 20 mg) and placebo. Prolactin measurements were taken at end-point in measurements were taken at end-point in 259 women. Levels in the risperidone group 259 women. Levels in the risperidone group were increased above the normal range in were increased above the normal range in proportion to the dose and their mean proportion to the dose and their mean was significantly higher than in women was significantly higher than in women treated with 10 mg (but not 20 mg) of halotreated with 10 mg (but not 20 mg) of haloperidol. Whether risperidone has a greater peridol. Whether risperidone has a greater effect on prolactin secretion than equivalent effect on prolactin secretion than equivalent doses of haloperidol, as reported in a small doses of haloperidol, as reported in a small 54-week continuation study (David 54-week continuation study (David et al et al, , 2000) , requires further study. 2000), requires further study.
In another study Breier In another study Breier et al et al (1999) (1999) measured prolactin levels in 29 men and measured prolactin levels in 29 men and women with chronic schizophrenia after a women with chronic schizophrenia after a 2-week standardising therapy with oral 2-week standardising therapy with oral fluphenazine (20 mg daily) and 6 weeks fluphenazine (20 mg daily) and 6 weeks after switching to clozapine (mean dose after switching to clozapine (mean dose 400 mg daily) or risperidone (mean dose 400 mg daily) or risperidone (mean dose 6 mg daily). At the end of fluphenazine 6 mg daily). At the end of fluphenazine treatment prolactin levels were increased treatment prolactin levels were increased by about twice the normal reference range by about twice the normal reference range in each group. After switching, levels in each group. After switching, levels decreased highly significantly into the nordecreased highly significantly into the normal reference range in the clozapine group, mal reference range in the clozapine group, whereas they did not change significantly in whereas they did not change significantly in the risperidone group. the risperidone group.
Preliminary evidence indicates that Preliminary evidence indicates that zotepine can also cause prolactin elevation zotepine can also cause prolactin elevation in humans after both acute and chronic in humans after both acute and chronic treatment (von Bardeleben treatment (von Bardeleben et al et al, 1987 However, this has not been systematically investigated. has not been systematically investigated.
The pharmacological basis of atypical The pharmacological basis of atypical antipsychotic action has been the target of antipsychotic action has been the target of intensive study, and various hypotheses intensive study, and various hypotheses have been put forward. These include a have been put forward. These include a relative limbic selectivity of these agents, a relative limbic selectivity of these agents, a separation of dose and response between separation of dose and response between pharmacological functions, interactions pharmacological functions, interactions with neurotransmitter receptors other than with neurotransmitter receptors other than D D 2 2 , and the binding dynamics at the D , and the binding dynamics at the D 2 2 receptor (Kapur & Seeman, 2001 ). receptor (Kapur & Seeman, 2001 ).
Although 5-HT Although 5-HT 2 2 receptors are involved receptors are involved in the stimulation of prolactin release, this in the stimulation of prolactin release, this usually occurs only at pharmacological usually occurs only at pharmacological levels of activation (van de Kar, 1991) . levels of activation (van de Kar, 1991) . The effect of antipsychotic agents such as The effect of antipsychotic agents such as risperidone on prolactin secretion cannot risperidone on prolactin secretion cannot be explained by their action on 5-HT be explained by their action on 5-HT 2 2 rereceptors, which is antagonistic and therefore ceptors, which is antagonistic and therefore more likely to inhibit prolactin secretion. more likely to inhibit prolactin secretion.
Other psychotropic medication Other psychotropic medication
Antidepressants with serotonergic activity, Antidepressants with serotonergic activity, including selective serotonin reuptake including selective serotonin reuptake inhibitors, monoamine oxidase inhibitors inhibitors, monoamine oxidase inhibitors and some tricyclic antidepressants, can and some tricyclic antidepressants, can cause modest elevations of prolactin levels cause modest elevations of prolactin levels (Checkley, 1991; Haddad & Wieck, (Checkley, 1991; Haddad & Wieck, 2000) . When these drugs are given as 2000). When these drugs are given as monotherapy patients have reported sympmonotherapy patients have reported symptoms of hyperprolactinaemia, but such toms of hyperprolactinaemia, but such reports are rare (Haddad & Wieck, 2000) . reports are rare (Haddad & Wieck, 2000) . In patients whose prolactin secretion is In patients whose prolactin secretion is already stimulated by antipsychotic drugs, already stimulated by antipsychotic drugs, serotonergic antidepressants have the serotonergic antidepressants have the potential to elevate prolactin levels above potential to elevate prolactin levels above the threshold for ovarian dysfunction and the threshold for ovarian dysfunction and galactorrhoea, or to worsen existing galactorrhoea, or to worsen existing symptoms. symptoms.
CONSEQUENCES OF CONSEQUENCES OF HYPERPROLACTINAEMIA HYPERPROLACTINAEMIA
Hyperprolactinaemia can cause breast Hyperprolactinaemia can cause breast enlargement and galactorrhoea, ovarian enlargement and galactorrhoea, ovarian dysfunction, infertility, reduced libido, dysfunction, infertility, reduced libido, atrophic changes in the urethra and vaginal atrophic changes in the urethra and vaginal mucosa, reduced vaginal lubrication and mucosa, reduced vaginal lubrication and dyspareunia. Acne and mild hirsutism can dyspareunia. Acne and mild hirsutism can develop, due to the relative increase of develop, due to the relative increase of androgenic compared with oestrogenic androgenic compared with oestrogenic activity. activity.
Research suggests that individuals vary Research suggests that individuals vary considerably in their sensitivity to hyperconsiderably in their sensitivity to hyperprolactinaemia and in the symptoms which prolactinaemia and in the symptoms which they develop. Of concern also are the they develop. Of concern also are the potential effects of chronic gonadal underpotential effects of chronic gonadal underfunction secondary to hyperprolactinaemia. function secondary to hyperprolactinaemia. Women with prolonged premenopausal Women with prolonged premenopausal oestrogen deficiency may be deprived of oestrogen deficiency may be deprived of the protective effects of oestrogen on cognithe protective effects of oestrogen on cognitive and cardiovascular function and may tive and cardiovascular function and may have an increased risk of osteoporosis. In have an increased risk of osteoporosis. In addition, chronically elevated prolactin addition, chronically elevated prolactin levels may have a number of as yet unlevels may have a number of as yet unknown physical effects. Binding sites for known physical effects. Binding sites for prolactin are widely distributed in the body prolactin are widely distributed in the body and several hundred different actions have and several hundred different actions have been described, at least in vertebrate anibeen described, at least in vertebrate animals (Bole-Feysot mals (Bole-Feysot et al et al, 1998) . Prolactin is , 1998). Prolactin is a known immunomodulator, for example, a known immunomodulator, for example, and has been linked to tumour growth. and has been linked to tumour growth. However, the clinical significance of these However, the clinical significance of these actions has not yet been firmly established. actions has not yet been firmly established.
Several studies have also reported an Several studies have also reported an association of hyperprolactinaemia with association of hyperprolactinaemia with hostility, anxiety and depression in women, hostility, anxiety and depression in women, although the severity of these symptoms although the severity of these symptoms appears to be mild (Sobrinho, 1993; appears to be mild (Sobrinho, 1993; Reavley Reavley et al et al, 1997) . , 1997).
Effects of hyperprolactinaemia Effects of hyperprolactinaemia on the hypothalamic^pituitaryôn the hypothalamic^pituitaryô varian axis ovarian axis A high prolactin concentration inhibits the A high prolactin concentration inhibits the activity of the hypothalamic-pituitaryactivity of the hypothalamic-pituitaryovarian axis at several levels. It suppresses ovarian axis at several levels. It suppresses the pulsatile release of gonadotrophinthe pulsatile release of gonadotrophinreleasing hormone (GnRH) from the releasing hormone (GnRH) from the hypothalamus, inhibits the effect of GnRH hypothalamus, inhibits the effect of GnRH on the pituitary gland and blocks the on the pituitary gland and blocks the positive feedback effect of oestradiol on positive feedback effect of oestradiol on luteinising hormone secretion. Women with luteinising hormone secretion. Women with prolactinoma usually seek medical attenprolactinoma usually seek medical attention as a result of menstrual disturbances, tion as a result of menstrual disturbances, galactorrhoea or infertility, but not if they galactorrhoea or infertility, but not if they are asymptomatic. It is therefore difficult are asymptomatic. It is therefore difficult to determine precisely the relationship to determine precisely the relationship between prolactin levels and symptom between prolactin levels and symptom formation. formation.
Five cross-sectional studies investigated Five cross-sectional studies investigated menstrual irregularities in women with menstrual irregularities in women with severe psychiatric illnesses receiving severe psychiatric illnesses receiving chronic treatment with various convenchronic treatment with various conventional antipsychotic agents at therapeutic tional antipsychotic agents at therapeutic dosages and found point prevalence rates dosages and found point prevalence rates of 26%, 40%, 45%, 55% and 78% respecof 26%, 40%, 45%, 55% and 78% respectively (Polishuk & Kulcsar, 1956; Ghadirtively (Polishuk & Kulcsar, 1956 (1999) only 36 of 451 women with chronic schizophrenia treated women with chronic schizophrenia treated with risperidone had a positive rating of with risperidone had a positive rating of amenorrhoea. This low rate (8%) was amenorrhoea. This low rate (8%) was similar to that seen in the haloperidol and similar to that seen in the haloperidol and placebo groups. The data are likely to be placebo groups. The data are likely to be an underestimate for several reasons: the an underestimate for several reasons: the placebo group consisted of only 14 women, placebo group consisted of only 14 women, and neither post-menopausal women nor and neither post-menopausal women nor the 20% of women on oral contraceptive the 20% of women on oral contraceptive medication were excluded. It is also not medication were excluded. It is also not clear whether the data refer to the prevaclear whether the data refer to the prevalence of these symptoms or to the number lence of these symptoms or to the number of new cases compared with the number of new cases compared with the number of cases receiving the antipsychotic of cases receiving the antipsychotic medication prior to the treatment trial. medication prior to the treatment trial. The latter method was used in an earlier The latter method was used in an earlier report for a subgroup of the same study report for a subgroup of the same study population (Peuskens, 1995) . For the two population (Peuskens, 1995) . For the two prolactin-raising atypical agents amisulprolactin-raising atypical agents amisulpride and zotepine, there is to our knowlpride and zotepine, there is to our knowledge no published study of sufficient edge no published study of sufficient duration that systematically investigates duration that systematically investigates the prevalence or incidence of menstrual the prevalence or incidence of menstrual irregularities. irregularities.
Clearly, hyperprolactinaemic symptoms Clearly, hyperprolactinaemic symptoms in psychiatric patients treated with antiin psychiatric patients treated with antipsychotic drugs are poorly researched. psychotic drugs are poorly researched. Several key problems are apparent. First, Several key problems are apparent. First, there is a paucity of data, reflecting the there is a paucity of data, reflecting the low priority given to this phenomenon. low priority given to this phenomenon. Second, many treatment trials simply reSecond, many treatment trials simply regard hyperprolactinaemia as a biochemical gard hyperprolactinaemia as a biochemical anomaly and do not comment on whether anomaly and do not comment on whether there were associated symptoms. Third, there were associated symptoms. Third, the short duration of even recent randomthe short duration of even recent randomised controlled trials (several weeks) means ised controlled trials (several weeks) means that it is an impossibility to identify amethat it is an impossibility to identify amenorrhoea or oligomenorrhoea, as these are norrhoea or oligomenorrhoea, as these are usually defined as occurring over a period usually defined as occurring over a period of at least 3 months. Fourth, the existing of at least 3 months. Fourth, the existing cross-sectional studies of women on longcross-sectional studies of women on longterm medication can only identify an term medication can only identify an association between raised prolactin level association between raised prolactin level and symptoms. Proving a causal relationship and symptoms. Proving a causal relationship requires a follow-up study to determine requires a follow-up study to determine whether reversal of hyperprolactinaemia is whether reversal of hyperprolactinaemia is accompanied by symptom resolution. No accompanied by symptom resolution. No such systematic study is recorded, but there such systematic study is recorded, but there are case reports of amenorrhoeic women are case reports of amenorrhoeic women with schizophrenia who resumed menstruawith schizophrenia who resumed menstruation after the antipsychotic medication was tion after the antipsychotic medication was discontinued or switched to a prolactindiscontinued or switched to a prolactinsparing agent (Beumont sparing agent (Beumont et al et al, 1974; Kim , 1974; Kim et al et al, 1999; Haddad , 1999; Haddad et al et al, 2001) . , 2001).
Other mechanisms Other mechanisms
Recent studies have challenged the view Recent studies have challenged the view that menstrual irregularities in women with that menstrual irregularities in women with schizophrenia are due to drug-induced schizophrenia are due to drug-induced prolactin elevation alone. In the study by prolactin elevation alone. In the study by ) some women with schizophrenia treated with prolactinwith schizophrenia treated with prolactinsparing antipsychotic agents also showed sparing antipsychotic agents also showed evidence of ovarian dysfunction. These evidence of ovarian dysfunction. These findings could indicate either that in findings could indicate either that in some some women an organic impairment leads women an organic impairment leads to both the schizophrenic illness and a to both the schizophrenic illness and a disturbance in the neuroendocrine reguladisturbance in the neuroendocrine regulation of ovarian activity, or that their tion of ovarian activity, or that their reproductive function might be affected by reproductive function might be affected by other mechanisms, such as stress resulting other mechanisms, such as stress resulting from the illness or even by an as yet unfrom the illness or even by an as yet unknown action of antipsychotic drugs on known action of antipsychotic drugs on hypothalamic-pituitary function. Irrespechypothalamic-pituitary function. Irrespective of the mechanisms, the data suggest tive of the mechanisms, the data suggest that the hypothalamic-pituitary system in that the hypothalamic-pituitary system in women with schizophrenia is particularly women with schizophrenia is particularly sensitive to further disturbances such as sensitive to further disturbances such as hyperprolactinaemia. hyperprolactinaemia.
Effects of hyperprolactinaemia Effects of hyperprolactinaemia on the breast on the breast
In most women who have given birth small In most women who have given birth small amounts of serous fluid can be expressed amounts of serous fluid can be expressed from one or both breasts despite normal from one or both breasts despite normal prolactin levels. However, significant milk prolactin levels. However, significant milk production usually occurs when prolactin production usually occurs when prolactin levels are above the normal reference range levels are above the normal reference range (Peters (Peters et al et al, 1986) . In women treated with , 1986). In women treated with conventional antipsychotic agents spontaconventional antipsychotic agents spontaneous galactorrhoea of varying severity neous galactorrhoea of varying severity has been reported to have a prevalence of has been reported to have a prevalence of 10-57% (Wesselmann & Windgassen, 10-57% (Wesselmann & Windgassen, 1995) . It is more likely to occur in women 1995). It is more likely to occur in women who have had children and are of premenowho have had children and are of premenopausal age (Windgassen pausal age (Windgassen et al et al, 1996) . The , 1996) . The low rate of galactorrhoea in the study by low rate of galactorrhoea in the study by Kleinberg Kleinberg et al et al (1999) -2.4% in women (1999) -2.4% in women treated with risperidone and 2.2% in treated with risperidone and 2.2% in women treated with haloperidol -may be women treated with haloperidol -may be an underestimate for the same reasons as an underestimate for the same reasons as described for the analysis of amenorrhoea. described for the analysis of amenorrhoea. Mammary side-effects of the other two Mammary side-effects of the other two prolactin-raising antipsychotics amisulpride prolactin-raising antipsychotics amisulpride and zotepine have not to our knowledge and zotepine have not to our knowledge been systematically studied. been systematically studied.
Hyperprolactinaemia and sexual Hyperprolactinaemia and sexual dysfunction dysfunction
Sexual dysfunction in patients with psySexual dysfunction in patients with psychosis is poorly researched, particularly in chosis is poorly researched, particularly in women, although existing data suggest that women, although existing data suggest that it is common and distressing. Ghadirian it is common and distressing. Ghadirian et al et al (1982) in a sample of 55 out-patients with (1982) in a sample of 55 out-patients with schizophrenia reported sexual dysfunction schizophrenia reported sexual dysfunction in 54% of men and 30% of women. In in 54% of men and 30% of women. In another study patients rated drug-induced another study patients rated drug-induced sexual dysfunction as more 'bothersome' sexual dysfunction as more 'bothersome' than most psychiatric symptoms of their illthan most psychiatric symptoms of their illness (Finn ness (Finn et al et al, 1990) . It would be reason-, 1990). It would be reasonable to expect that this symptom plays a able to expect that this symptom plays a prominent part in determining adherence prominent part in determining adherence to medication regimens, although no formal to medication regimens, although no formal research has addressed this relationship, to research has addressed this relationship, to the best of our knowledge. the best of our knowledge.
There are several mechanisms by which There are several mechanisms by which sexual dysfunction might arise in a person sexual dysfunction might arise in a person with a psychotic illness. These include the with a psychotic illness. These include the social impact of the illness, the effects of social impact of the illness, the effects of psychiatric symptoms (positive, negative, psychiatric symptoms (positive, negative, affective and cognitive), neurotransmitter affective and cognitive), neurotransmitter dysfunction and medication effects. The latdysfunction and medication effects. The latter include peripheral and central effects ter include peripheral and central effects (e.g. sedation, and antidopaminergic, anti-(e.g. sedation, and antidopaminergic, anticholinergic and anti-adrenergic activity) as cholinergic and anti-adrenergic activity) as well as hyperprolactinaemia. The existence well as hyperprolactinaemia. The existence of these different mechanisms means that in of these different mechanisms means that in some people antipsychotic medication some people antipsychotic medication might improve sexual functioning commight improve sexual functioning compared with the period when they were pared with the period when they were psychiatrically ill but untreated, but in psychiatrically ill but untreated, but in other people medication might cause a other people medication might cause a worsening of sexual functioning even if worsening of sexual functioning even if the medication is effective in treating their the medication is effective in treating their illness (Barnes & Harvey, 1993) . illness (Barnes & Harvey, 1993) .
There is some evidence to support the There is some evidence to support the view that hyperprolactinaemia can cause view that hyperprolactinaemia can cause sexual dysfunction, although the evidence is sexual dysfunction, although the evidence is more consistent for men than for women. more consistent for men than for women. Lundberg & Hulter (1991) reported that 68 Lundberg & Hulter (1991) reported that 68 of 109 women (62%) with hypothalamicof 109 women (62%) with hypothalamicpituitary disorders experienced decreased pituitary disorders experienced decreased libido. Among women with hyperprolibido. Among women with hyperprolactinaemia the prevalence was 84% but lactinaemia the prevalence was 84% but in those with normal prolactin levels the in those with normal prolactin levels the prevalence was only 32.6% ( prevalence was only 32.6% (P P5 50.001). 0.001). Whether this difference was due to Whether this difference was due to hyperprolactinaemia itself, reduced ovarian hyperprolactinaemia itself, reduced ovarian hormone production, or both, is not clear. hormone production, or both, is not clear.
Effects of hypo-oestrogenism
Effects of hypo-oestrogenism on bone mineral density on bone mineral density Radiologically measured bone mineral denRadiologically measured bone mineral density (BMD) is an index of bone mass and is sity (BMD) is an index of bone mass and is calculated by dividing the mineral content calculated by dividing the mineral content by the area or volume of bone scanned. by the area or volume of bone scanned. Techniques commonly used are single or Techniques commonly used are single or dual-energy X-ray absorptiometry and dual-energy X-ray absorptiometry and computed tomographic scanning. Density computed tomographic scanning. Density is at its peak and is relatively constant beis at its peak and is relatively constant between the end of growth and the age of tween the end of growth and the age of about 50 years, and values are normally about 50 years, and values are normally distributed in women of this age group. distributed in women of this age group.
In order to overcome the problems In order to overcome the problems associated with using different types of associated with using different types of equipment, results of BMD measurements equipment, results of BMD measurements are usually expressed in units of standard are usually expressed in units of standard deviations above or below the mean value deviations above or below the mean value of young healthy populations (the T-score) of young healthy populations (the T-score) or an age-adjusted mean value (the Zor an age-adjusted mean value (the Zscore). For diagnostic purposes two threshscore). For diagnostic purposes two thresholds are used: a T-score of olds are used: a T-score of 7 72.5 or less 2.5 or less denotes 'osteoporosis' and a T-score that denotes 'osteoporosis' and a T-score that lies between lies between 7 71 and 1 and 7 72.49 denotes 'osteo-2.49 denotes 'osteopenia'. The BMD value can be used to penia'. The BMD value can be used to predict the risk of later fractures and it predict the risk of later fractures and it has been calculated that -at the most has been calculated that -at the most vulnerable sites -the risk of fracture vulnerable sites -the risk of fracture approximately doubles with each standard approximately doubles with each standard deviation of decrease in age-adjusted mean deviation of decrease in age-adjusted mean BMD (Royal College of Physicians, 1999). BMD (Royal College of Physicians, 1999) .
In adult life, bone is continually remoIn adult life, bone is continually remodelled by resorption and new tissue formadelled by resorption and new tissue formation. It has been estimated that in humans tion. It has been estimated that in humans as much as 25% of trabecular bone and as much as 25% of trabecular bone and 3% of cortical bone are resorbed and re-3% of cortical bone are resorbed and replaced each year (Parfitt, 1994) . Oestrogens placed each year (Parfitt, 1994) . Oestrogens have a major role in regulating this process. have a major role in regulating this process. If oestrogen action is reduced, bone resorpIf oestrogen action is reduced, bone resorption increases relative to new bone formation increases relative to new bone formation. This results in loss of tissue and tion. This results in loss of tissue and of integrity of the microarchitecture of of integrity of the microarchitecture of trabecular bone. Bone becomes more sustrabecular bone. Bone becomes more susceptible to stress and may fracture even ceptible to stress and may fracture even after trivial trauma. after trivial trauma.
The oestrogen deficiency associated The oestrogen deficiency associated with the menopause leads to an accelerawith the menopause leads to an acceleration in age-related bone loss that can be tion in age-related bone loss that can be halted by hormone replacement therapy. halted by hormone replacement therapy. A similar process occurs in premenopausal A similar process occurs in premenopausal women with hyperprolactinaemic oestrowomen with hyperprolactinaemic oestrogen deficiency due to hypothalamic lesions gen deficiency due to hypothalamic lesions or of idiopathic origin. In such patients, or of idiopathic origin. In such patients, radiological studies have shown significant radiological studies have shown significant decreases in bone mineral content, ranging decreases in bone mineral content, ranging from 5% to 25% depending on the site from 5% to 25% depending on the site measured (Koppelman measured (Koppelman et al et al 1984; Schlechte 1984; Schlechte et al et al, 1987) . If prolactin levels and menstru-, 1987) . If prolactin levels and menstrual cycles normalise with treatment, BMD al cycles normalise with treatment, BMD values increase but remain significantly values increase but remain significantly lower than those of age-matched normal lower than those of age-matched normal women (Klibanski & Greenspan, 1986; women (Klibanski & Greenspan, 1986; Schlechte Schlechte et al et al, 1987) . , 1987). Psychiatric patients often commence Psychiatric patients often commence antipsychotic medication in their late teens antipsychotic medication in their late teens or early twenties and owing to oestrogen or early twenties and owing to oestrogen deficiency may not only acquire a reduced deficiency may not only acquire a reduced peak bone mass but also have a premature peak bone mass but also have a premature acceleration of bone loss. The future lifeacceleration of bone loss. The future lifetime risk of fracture for an average, healthy time risk of fracture for an average, healthy 50-year-old woman is 13%, 11% and 14% 50-year-old woman is 13%, 11% and 14% for the three most vulnerable sites -forefor the three most vulnerable sites -forearm, vertebrae and femoral neck (Royal arm, vertebrae and femoral neck (Royal College of Physicians, 1999) . In a female College of Physicians, 1999) . In a female psychiatric patient, if the BMD at the age psychiatric patient, if the BMD at the age of 50 years were to be reduced by 1 s.d. of 50 years were to be reduced by 1 s.d. her future risk of fracture at these sites her future risk of fracture at these sites might be doubled. might be doubled.
In addition to drug-induced gonadal In addition to drug-induced gonadal dysfunction psychiatric patients are exdysfunction psychiatric patients are exposed to other risks to bone health, particuposed to other risks to bone health, particularly excessive nicotine and alcohol larly excessive nicotine and alcohol consumption, and inadequate dietary calconsumption, and inadequate dietary calcium and protein intake (Peris cium and protein intake (Peris et al et al, 1992; , 1992; Hopper & Seeman, 1994) . Hopper & Seeman, 1994) .
Studies of bone density Studies of bone density in psychiatric patients in psychiatric patients
In women exposed to antipsychotic In women exposed to antipsychotic medication bone density has been assessed medication bone density has been assessed in two studies. Ataya in two studies. Ataya et al et al (1988 Ataya et al et al ( ) assessed (1988 assessed ten premenopausal women who had been ten premenopausal women who had been treated with antipsychotic drugs for an treated with antipsychotic drugs for an average of 10 years and had developed average of 10 years and had developed amenorrhoea or oligomenorrhoea. Measureamenorrhoea or oligomenorrhoea. Measurements of BMD were taken from the whole ments of BMD were taken from the whole spine and the femoral head and neck using spine and the femoral head and neck using dual-photon absorptiometry. Data were dual-photon absorptiometry. Data were compared with age-and gender-related compared with age-and gender-related normative values from a large database. normative values from a large database. Bone density was reduced by about 12% Bone density was reduced by about 12% 2 0 2 2 0 2 at three sites of the femur, but not in the at three sites of the femur, but not in the spine. Although oestradiol levels were not spine. Although oestradiol levels were not measured, there was a strong positive measured, there was a strong positive correlation between bone density and a correlation between bone density and a histological measure of vaginal maturation histological measure of vaginal maturation used as an index of the biological effects used as an index of the biological effects of oestrogens. Halbreich of oestrogens. Halbreich et al et al (1995) found (1995) found significantly reduced BMD values in the significantly reduced BMD values in the lumbar spine in a group of women treated lumbar spine in a group of women treated with antipsychotic, antidepressant and with antipsychotic, antidepressant and mood-stabilising medication, either alone mood-stabilising medication, either alone or in combination. However, the contrior in combination. However, the contribution of an endocrine dysfunction cannot bution of an endocrine dysfunction cannot be interpreted in this study since no inforbe interpreted in this study since no information was given on the presence or mation was given on the presence or duration of menstrual cycle disturbances duration of menstrual cycle disturbances and the duration of psychotropic treatment and the duration of psychotropic treatment prior to admission. prior to admission.
In patients with major depression bone In patients with major depression bone mineral densities have been reported to be mineral densities have been reported to be reduced and it is thought that this is due reduced and it is thought that this is due to hypercortisolism and changes in cytokine to hypercortisolism and changes in cytokine activity (see Dinan, 1999) . Although deactivity (see Dinan, 1999) . Although depression is common in schizophrenia it is pression is common in schizophrenia it is unlikely to contribute to bone loss since unlikely to contribute to bone loss since it is not associated with alterations in it is not associated with alterations in hypothalamic-pituitary-adrenal function hypothalamic-pituitary-adrenal function in these patients (Rao in these patients (Rao et al et al, 1995; Ismail , 1995; Ismail et al et al, 1998) .
, 1998). The findings of reduced BMD in The findings of reduced BMD in patients treated with antipsychotics are patients treated with antipsychotics are preliminary and suffer from small sample preliminary and suffer from small sample sizes and methodological shortcomings. sizes and methodological shortcomings. However, they are of concern and need to However, they are of concern and need to be followed up in future studies of people be followed up in future studies of people with homogeneous diagnoses and psychowith homogeneous diagnoses and psychotropic treatments, and clear histories of tropic treatments, and clear histories of prolonged oestrogen deficiency confirmed prolonged oestrogen deficiency confirmed by hormone measurements. by hormone measurements.
Study Group (1997) 
The effects of olanzapine, risperidone, and haloperidol The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. on plasma prolactin levels in patients with schizophrenia. The presence of menstrual irregularities, breast symptoms and sexual dysfunction should be assessed before and during treatment with prolactin-elevating drugs and should be assessed before and during treatment with prolactin-elevating drugs and management options should be discussed with the patient. management options should be discussed with the patient. In women with schizophrenia it is not yet clear how much medication effects other than hyperprolactinaemia and illness-related organic processes contribute to ovarian than hyperprolactinaemia and illness-related organic processes contribute to ovarian dysfunction. dysfunction.
